DMH-25

CAS No. 1685280-21-0

DMH-25( —— )

Catalog No. M22216 CAS No. 1685280-21-0

DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 178 Get Quote
5MG 268 Get Quote
10MG 408 Get Quote
25MG 672 Get Quote
50MG 945 Get Quote
100MG 1278 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    DMH-25
  • Note
    Research use only, not for human use.
  • Brief Description
    DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology.
  • Description
    DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells.In vivo, DHM25 was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    mTOR
  • Recptor
    mTOR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1685280-21-0
  • Formula Weight
    489.94
  • Molecular Formula
    C15H8Br3NO3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=[N+](C(C(C1=CC=C(Br)C=C1)O2)=CC3=C2C(Br)=CC(Br)=C3)[O-]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.amélie, fouqué, Delalande O , Jean M , et al. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells[J]. Journal of Medicinal Chemistry, 2015:6559-73.
molnova catalog
related products
  • Autogramin-1

    Autogramin-1 potently inhibits starvation-induced autophagy with IC50 of 0.17 μM.

  • Seco Rapamycin sodiu...

    Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.

  • Cbz-B3A

    Cbz-B3A is a potent inhibitor of mTORC1 signalling, inhibits phosphorylation of eIF4E-binding protein 1 (4EBP1) and blocks translation by 68%.